Tower Research Capital LLC TRC Has $47,000 Holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS)

Tower Research Capital LLC TRC raised its position in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 109.2% in the fourth quarter, HoldingsChannel reports. The fund owned 5,299 shares of the biotechnology company’s stock after purchasing an additional 2,766 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Astria Therapeutics were worth $47,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in ATXS. KLP Kapitalforvaltning AS acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $41,000. Teacher Retirement System of Texas acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $91,000. New York State Common Retirement Fund grew its stake in Astria Therapeutics by 67.0% in the fourth quarter. New York State Common Retirement Fund now owns 10,720 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 4,300 shares during the period. China Universal Asset Management Co. Ltd. acquired a new stake in Astria Therapeutics in the fourth quarter valued at approximately $107,000. Finally, SG Americas Securities LLC boosted its position in shares of Astria Therapeutics by 51.3% during the fourth quarter. SG Americas Securities LLC now owns 21,296 shares of the biotechnology company’s stock valued at $190,000 after buying an additional 7,218 shares during the last quarter. Institutional investors and hedge funds own 98.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on ATXS shares. Cantor Fitzgerald raised Astria Therapeutics to a “strong-buy” rating in a research report on Tuesday, April 29th. Citizens Jmp raised Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Tuesday, March 11th. JMP Securities started coverage on Astria Therapeutics in a research report on Friday, January 31st. They set an “outperform” rating and a $26.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $28.00 target price (up previously from $27.00) on shares of Astria Therapeutics in a research report on Wednesday, March 12th. Five analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $30.00.

Astria Therapeutics Trading Up 3.3%

Shares of Astria Therapeutics stock opened at $4.37 on Tuesday. The business’s fifty day simple moving average is $5.19 and its 200 day simple moving average is $7.56. The firm has a market capitalization of $246.62 million, a P/E ratio of -2.09 and a beta of 0.45. Astria Therapeutics, Inc. has a 12 month low of $3.56 and a 12 month high of $12.92.

Astria Therapeutics (NASDAQ:ATXS) last issued its quarterly earnings results on Tuesday, March 11th. The biotechnology company reported ($0.44) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.01. Analysts predict that Astria Therapeutics, Inc. will post -1.65 EPS for the current fiscal year.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.